NCT02700334View on ClinicalTrials.gov

Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

February 28, 2017

Conditions
PrediabetesImpaired Fasting GlucoseImpaired Glucose Tolerance
Interventions
DRUG

Dapagliflozin

10 mg, one per day before breakfast during 12 weeks.

DRUG

Placebo

one per day before breakfast during 12 weeks.

Trial Locations (1)

44340

Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara

All Listed Sponsors
lead

University of Guadalajara

OTHER

NCT02700334 - Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes | Biotech Hunter | Biotech Hunter